(OTTAWA, ON. – December 1, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has appointed Andrea Greenberg as vice president, Strategic Services.
“We are thrilled to have Andrea join the BWXT Medical leadership team and know that her extensive experience aligns perfectly with our strategic growth initiatives for the business,” said Jonathan Cirtain, president & CEO of BWXT Medical. “In particular, Andrea will be a strong asset for our near-term scale-up activities across multiple pipeline products currently in development at BWXT Medical.”
Greenberg spent over 20 years with Cardinal Health in various roles of increasing responsibility largely in program and project management, most recently in Nuclear & Precision Health Solutions. Among Greenberg’s many accomplishments is having overseen the start-up of the contract manufacturing of Xofigo®, an alpha-particle-emitting radioactive therapeutic agent for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease, for Bayer HealthCare. Further, Greenberg also oversaw the design and build of two additional multi-use radiopharmaceutical manufacturing facilities and numerous technology transfers for theranostic drug product innovators.
About BWXT
At BWX Technologies, Inc. (NYSE: BWXT), we are People Strong, Innovation Driven. Headquartered in Lynchburg, Virginia, BWXT is a Fortune 1000 and Defense News Top 100 manufacturing and engineering innovator that provides safe and effective nuclear solutions for global security, clean energy, environmental remediation, nuclear medicine and space exploration. With approximately 6,700 employees, BWXT has 14 major operating sites in the U.S., Canada and the U.K. In addition, BWXT joint ventures provide management and operations at more than a dozen U.S. Department of Energy and NASA facilities. Follow us on Twitter at @BWXT and learn more at www.bwxt.com.
#
Media Contact
Chris Dumond
Manager, Communications
434.522.5015
[email protected]